These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15388473)

  • 1. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
    Credito K; Lin G; Ednie LM; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4033-6. PubMed ID: 15388473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
    Ednie LM; Pankuch G; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4027-32. PubMed ID: 15388472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
    Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of LBM415 compared to those of 11 other agents against Haemophilus species.
    Bogdanovich T; Smith KA; Clark C; Pankuch GA; Lin G; McGhee P; Dewasse B; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2323-9. PubMed ID: 16801408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin.
    Hoellman DB; Pankuch GA; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4037-9. PubMed ID: 15388474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.
    Lin G; Credito K; Ednie LM; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Feb; 49(2):770-2. PubMed ID: 15673763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis.
    Lemaire S; Kosowska-Shick K; Julian K; Tulkens PM; Van Bambeke F; Appelbaum PC
    Clin Microbiol Infect; 2008 Aug; 14(8):766-77. PubMed ID: 18727801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415.
    Dean CR; Narayan S; Daigle DM; Dzink-Fox JL; Puyang X; Bracken KR; Dean KE; Weidmann B; Yuan Z; Jain R; Ryder NS
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3129-35. PubMed ID: 16048914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center.
    Bozdogan B; Esel D; Whitener C; Browne FA; Appelbaum PC
    J Antimicrob Chemother; 2003 Nov; 52(5):864-8. PubMed ID: 14563898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
    Leuthner KD; Cheung CM; Rybak MJ
    J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
    Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
    J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G; White R; Friedrich L
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
    Jørgen B; Merckoll P; Melby KK
    Scand J Infect Dis; 2007; 39(11-12):1059-62. PubMed ID: 17852934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
    Fritsche TR; Sader HS; Cleeland R; Jones RN
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1468-76. PubMed ID: 15793128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis.
    Lin G; Appelbaum PC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):233-5. PubMed ID: 17997257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.
    Osborne CS; Neckermann G; Fischer E; Pecanka R; Yu D; Manni K; Goldovitz J; Amaral K; Dzink-Fox J; Ryder NS
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3777-81. PubMed ID: 19596876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.
    Jones RN; Moet GJ; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2004 May; 53(5):804-7. PubMed ID: 15056649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
    Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
    Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.